Focus On: How Dr. Reddy’s Labs’ approach sets it apart in a crowded spaceOfficials at Dr. Reddy’s are doing all they can to make sure the company is at the top of the list when retail pharmacists are seeking a business partner in the complicated and unique world of generic drug manufacturing. Virtual roundtable: State of the generics industryExecutives from leading generics firms weigh in on what the future holds for the industry and what hurdles will have to be overcome. Alembic debuts generic Symmetrel Alembic's generic Symmetrel is available in a dosage strength of 100 mg in 100-count bottles. Lupin gets FDA nod for generic Kerydin Tavaborole topical solution had a market value of roughly $76 million, according to IQVIA December 2020 data. Lannett expands strategic relationship with HEC for biosimilar Aspart Lannett and HEC will co-develop biosimilar insulin Aspart, with Lannett possessing exclusive U.S. commercialization rights. Lannett intros generic Thorazine Thorazine had a market value of approximately $120 million for the 12 months ended November 2020, according to IQVIA, although actual generic market values are expected to be lower. Hikma intros ephedrine sulfate Ephedrine sulfate injection had a market value of approximately $64 million in the 12 months ended November 2020, according to IQVIA. Unichem gets FDA OK for generic Celebrex Unichem's generic Celebrex will be available in four dosage strengths: 50 mg, 100 mg, 200 mg, and 400 mg. Sandoz, Slayback Pharma partner to launch generic Firazyr Sandoz has signed a U.S. commercialization deal with Slayback Pharma to launch generic Firazyr (icatibant injection). What’s in store: Pharmacy execs size up the industry in the wake of 2020 Drug Store News reached out to a number of key industry executives to get their sense of how the pharmacy industry managed in 2020. First Previous 119 120 121 122 123 Next Last